$CRYM
Cryomass Technologies, Inc. Stock $crym

$crym Overview Financials Valuation SEC Filings Company Website

2024 Q4 Form 10-Q Financial Statement

#000121390024095916 Filed on November 08, 2024

Income Statement

Concept	2024 Q4	2024 Q3	2023 Q3
Revenue		$5.000K	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit		$5.000K
YoY Change
Gross Profit Margin		100.0%
Selling, General & Admin			$470.0K
YoY Change			-5.38%
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization		$13.08K	$13.08K
YoY Change		0.0%	-40.12%
% of Gross Profit		261.54%
Operating Expenses		$870.9K	$1.373M
YoY Change		-36.59%	9.53%
Operating Profit		-$865.9K	-$1.373M
YoY Change		-36.95%	9.53%
Interest Expense			$109.3K
YoY Change			330.15%
% of Operating Profit
Other Income/Expense, Net		-$236.1K	-$80.56K
YoY Change		193.03%	-417.01%
Pretax Income		-$1.102M	-$1.450M
YoY Change		-24.0%	18.04%
Income Tax
% Of Pretax Income
Net Earnings		-$1.102M	-$1.454M
YoY Change		-24.21%	18.35%
Net Earnings / Revenue		-22038.66%
Basic Earnings Per Share		$0.00	-$0.01
Diluted Earnings Per Share		$0.00	-$0.01
COMMON SHARES
Basic Shares Outstanding	237.2M shares	235.3M shares	206.2M shares
Diluted Shares Outstanding		237.0M shares	207.4M shares

Balance Sheet

Concept	2024 Q3	2023 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments		$10.00K
YoY Change		-99.68%
Cash & Equivalents	$183.4K	$9.485K
Short-Term Investments
Other Short-Term Assets		$210.0K
YoY Change		53.69%
Inventory
Prepaid Expenses	$106.6K	$190.8K
Receivables	$6.189K
Other Receivables
Total Short-Term Assets	$296.3K	$222.1K
YoY Change	33.38%	-93.2%
LONG-TERM ASSETS
Property, Plant & Equipment	$787.8K	$736.1K
YoY Change	7.01%	110.58%
Goodwill	$0.00
YoY Change
Intangibles		$114.0K
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$833.4K	$850.2K
YoY Change	-1.98%	-91.31%
TOTAL ASSETS
Total Short-Term Assets	$296.3K	$222.1K
Total Long-Term Assets	$833.4K	$850.2K
Total Assets	$1.130M	$1.072M
YoY Change	5.35%	-91.78%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable		$1.730M
YoY Change		40.08%
Accrued Expenses
YoY Change
Deferred Revenue	$886.7K
YoY Change
Short-Term Debt		$386.5K
YoY Change
Long-Term Debt Due		$230.0K
YoY Change
Total Short-Term Liabilities	$7.243M	$1.980M
YoY Change	265.87%	60.3%
LONG-TERM LIABILITIES
Long-Term Debt		$2.430M
YoY Change		21.5%
Other Long-Term Liabilities		$80.00K
YoY Change
Total Long-Term Liabilities		$2.510M
YoY Change		25.5%
TOTAL LIABILITIES
Total Short-Term Liabilities	$7.243M	$1.980M
Total Long-Term Liabilities		$2.510M
Total Liabilities	$10.57M	$4.490M
YoY Change	135.41%	38.8%
SHAREHOLDERS EQUITY
Retained Earnings	-$57.24M	-$48.43M
YoY Change	18.21%	44.99%
Common Stock	$237.2K	$210.0K
YoY Change	12.92%	3.71%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$9.440M	-$3.418M
YoY Change
Total Liabilities & Shareholders Equity	$1.130M	$1.072M
YoY Change	5.35%	-91.78%

Cashflow Statement

Concept	2024 Q3	2023 Q3
OPERATING ACTIVITIES
Net Income	-$1.102M	-$1.454M
YoY Change	-24.21%	18.35%
Depreciation, Depletion And Amortization	$13.08K	$13.08K
YoY Change	0.0%	-40.12%
Cash From Operating Activities		-$870.0K
YoY Change		-1.69%
INVESTING ACTIVITIES
Capital Expenditures		$20.00K
YoY Change		-159.07%
Acquisitions
YoY Change
Other Investing Activities		$0.00
YoY Change
Cash From Investing Activities		-$20.00K
YoY Change		-40.93%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities		590.0K
YoY Change		-68.29%
NET CHANGE
Cash From Operating Activities		-870.0K
Cash From Investing Activities		-20.00K
Cash From Financing Activities		590.0K
Net Change In Cash		-300.0K
YoY Change		-131.86%
FREE CASH FLOW
Cash From Operating Activities		-$870.0K
Capital Expenditures		$20.00K
Free Cash Flow		-$890.0K
YoY Change		4.57%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold		usd
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold		usd
CY2023Q3	us-gaap	Gross Profit GrossProfit		usd
	us-gaap	Gross Profit GrossProfit		usd
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding		shares
	us-gaap	Revenues Revenues		usd
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold		usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense		usd
CY2023Q3	us-gaap	Revenues Revenues		usd
CY2024Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold		usd
CY2024Q3	us-gaap	Notes Payable Current NotesPayableCurrent		usd
CY2024Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2024Q3	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2024Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued		shares
CY2024Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding		shares
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued		shares
CY2023Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense		usd
CY2024Q3	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill		usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	-3417802	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-5849242	usd
CY2024Q1	crym	Adjustment To Additional Capital Stock Options Issued For Current Period Services AdjustmentToAdditionalCapitalStockOptionsIssuedForCurrentPeriodServices	57557	usd
CY2024Q1	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition	28226	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-2554469	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	-8317928	usd
CY2024Q2	crym	Common Stock And Warrants Issued For Prior Period Services CommonStockAndWarrantsIssuedForPriorPeriodServices	50000	usd
CY2024Q2	crym	Adjustment To Additional Capital Stock Options Issued For Current Period Services AdjustmentToAdditionalCapitalStockOptionsIssuedForCurrentPeriodServices	18915	usd
CY2024Q2	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition	25000	usd
CY2024Q2	crym	Share Issuance From Sale Of Common Stock And Warrants ShareIssuanceFromSaleOfCommonStockAndWarrants	708151	usd
CY2024Q2	crym	Share Issuance From Debt Cancellation ShareIssuanceFromDebtCancellation	678279	usd
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	-1619727	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	-8457310	usd
CY2024Q3	crym	Adjustment To Additional Capital Stock Options Issued For Current Period Services AdjustmentToAdditionalCapitalStockOptionsIssuedForCurrentPeriodServices	18915	usd
CY2024Q3	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition	25000	usd
CY2024Q3	crym	Share Issuance From Sale Of Common Stock And Warrants ShareIssuanceFromSaleOfCommonStockAndWarrants	75000	usd
CY2024Q3	us-gaap	Net Income Loss NetIncomeLoss	-1101933	usd
CY2024Q3	us-gaap	Stockholders Equity StockholdersEquity	-9440328	usd
	us-gaap	Net Income Loss NetIncomeLoss	-5276129	usd
	us-gaap	Net Income Loss NetIncomeLoss	-9414198	usd
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	92960	usd
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	34964	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	90536	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	299044	usd
	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	1282	usd
	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	5972	usd
	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	1190000	usd
	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	3653043	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-338897	usd
	crym	Gain Losson Contingent Royalty Liability GainLossonContingentRoyaltyLiability	-1487082	usd
	us-gaap	Paid In Kind Interest PaidInKindInterest	267359	usd
	crym	Common Stock Issued For Vested Rs Us For Current Period Service CommonStockIssuedForVestedRSUsForCurrentPeriodService	131304	usd
	crym	Stockbased Compensation For Vested Rs Us For Current Period Services StockbasedCompensationForVestedRSUsForCurrentPeriodServices	78226	usd
	crym	Stockbased Compensation For Vested Rs Us For Current Period Services StockbasedCompensationForVestedRSUsForCurrentPeriodServices	378508	usd
	crym	Stock Options Issued For Current Period Services StockOptionsIssuedForCurrentPeriodServices	95387	usd
	crym	Stock Options Issued For Current Period Services StockOptionsIssuedForCurrentPeriodServices	177989	usd
	crym	Adjustment Of Common Stock And Warrants Issued For Prior Period Services AdjustmentOfCommonStockAndWarrantsIssuedForPriorPeriodServices	-50000	usd
	crym	Common Stock Issued For The Current Period Services CommonStockIssuedForTheCurrentPeriodServices	85738	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-2363	usd
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	11881	usd
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	62194	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	1309780	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	219805	usd
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	931688	usd
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	100000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-545014	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-3211969	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	103922	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	25000	usd
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	49236	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-103922	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-74236	usd
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	875991	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	783151	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	387642	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	16000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	783151	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1279633	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	134215	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-2006572	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	49224	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2016057	usd
CY2024Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	183439	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	9485	usd
	us-gaap	Noncash Or Part Noncash Acquisition Payables Assumed1 NoncashOrPartNoncashAcquisitionPayablesAssumed1	3252	usd
	us-gaap	Noncash Or Part Noncash Acquisition Payables Assumed1 NoncashOrPartNoncashAcquisitionPayablesAssumed1	221577	usd
	crym	Debt Discount Recognized From Warrants Issued In Conjunction With Notes Payable DebtDiscountRecognizedFromWarrantsIssuedInConjunctionWithNotesPayable	244747	usd
	crym	Stock Issued For Cancellation Of Debt StockIssuedForCancellationOfDebt	339082	usd
	us-gaap	Nature Of Operations NatureOfOperations	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>1. Nature of the Business</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Cryomass Technologies Inc. (the “Company”) develops and licenses cutting-edge equipment and processes to refine harvested cannabis, hemp, and other premium crops. The Company’s patented technology harnesses liquid nitrogen to reduce biomass and then efficiently isolate, collect and preserve delicate resin glands (trichomes) containing prized compounds like cannabinoids and terpenes. Building on this technology, Cryomass has engineered its premier Trichome Separation unit (CryoSift Separator™), optimized via patented cryogenic processes to rapidly capture intact, high-value cannabis and hemp trichomes (CryoSift™).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company’s principal office is located at 1001 Bannock St., Suite 612, Denver, CO 80204, and its telephone number is 303-416-7208. The Company’s website is www.cryomass.com. Information appearing on the website is not incorporated by reference into this report.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Cryomass Technologies Inc. is the parent company to wholly-owned subsidiaries Cryomass LLC, Cryomass California LLC, and 1304740 B.C. Unlimited Liability Company dba Cryomass Canada.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On June 22, 2021, the Company entered into an Asset Purchase Agreement with Cryocann USA Corp, a California corporation (“Cryocann”), pursuant to which Company acquired substantially all the assets of Cryocann. The acquired assets included the patented cryogenic process titled “System and method for cryogenic separation of plant material” (US patent #10,864,525) for the reduction of biomass and efficient isolation, collection and preservation of delicate resin glands (trichomes) of harvested of hemp and cannabis, and potentially other high value trichome-rich plants.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In September 2021, we were granted an additional patent for our process from the Chinese Intellectual Property Office. In April 2022, we were granted another patent #3,064,896 from the Canadian Intellectual Property Office. We currently are taking steps to gain further protection for our intellectual property through the European Union Intellectual Property Office and other international jurisdictions.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The first production commercial unit, known as a CryoSift Separator™, is expected to be delivered in the fourth quarter of 2024. The existing beta unit of the respective CryoSift Separator™ is expected to be installed at a business partner’s location in California for demonstration purposes also in the fourth quarter of 2024.</p>
	crym	Working Deficit WorkingDeficit	6946821	usd
CY2024Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	183439	usd
	crym	Overhead Costs OverheadCosts	3600000	usd
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	2700000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-545014	usd
	us-gaap	Net Income Loss NetIncomeLoss	-5276129	usd
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2024-09-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	000-56155
	dei	Entity Registrant Name EntityRegistrantName	CRYOMASS TECHNOLOGIES INC.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NV
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	82-5051728
	dei	Entity Address Address Line1 EntityAddressAddressLine1	1001 Bannock Street
	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 612
	dei	Entity Address City Or Town EntityAddressCityOrTown	Denver
	dei	Entity Address State Or Province EntityAddressStateOrProvince	CO
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	80204
	dei	City Area Code CityAreaCode	303
	dei	Local Phone Number LocalPhoneNumber	416-7208
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2024Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	237159877	shares
CY2024Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	183439	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	49224	usd
CY2024Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	6189	usd
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	8552	usd
CY2024Q3	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	106627	usd
CY2023Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	94746	usd
CY2024Q3	us-gaap	Assets Current AssetsCurrent	296255	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	152522	usd
CY2024Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	787764	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	723072	usd
CY2024Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	45606	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	96912	usd
CY2024Q3	us-gaap	Assets Assets	1129625	usd
CY2023Q4	us-gaap	Assets Assets	972506	usd
CY2024Q3	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	3546243	usd
CY2023Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	2236462	usd
CY2024Q3	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	886688	usd
CY2023Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	20000	usd
CY2024Q3	crym	Contract With Customer Liability Related Partycurrent ContractWithCustomerLiabilityRelatedPartycurrent	80000	usd
CY2023Q4	us-gaap	Notes Payable Current NotesPayableCurrent	237500	usd
CY2024Q3	us-gaap	Liabilities Current LiabilitiesCurrent	7243076	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	2493962	usd
CY2024Q3	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	60000	usd
CY2023Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	75000	usd
CY2024Q3	us-gaap	Long Term Notes Payable LongTermNotesPayable	594795	usd
CY2023Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	597381	usd
CY2024Q3	crym	Contingent Royalty Liability ContingentRoyaltyLiability	2672082	usd
CY2023Q4	crym	Contingent Royalty Liability ContingentRoyaltyLiability	1185000	usd
CY2024Q3	us-gaap	Liabilities Liabilities	10569953	usd
CY2023Q4	us-gaap	Liabilities Liabilities	6821748	usd
CY2024Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2024Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-57243385	usd
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2024Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	100000	shares
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	100000	shares
CY2024Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2024Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2024Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	237159877	shares
CY2024Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	237159877	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	210032401	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	210032401	shares
CY2024Q3	us-gaap	Common Stock Value CommonStockValue	237161	usd
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	210033	usd
CY2024Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	47565896	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	45907981	usd
CY2024Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-57243385	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-51967256	usd
CY2024Q3	us-gaap	Stockholders Equity StockholdersEquity	-9440328	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-5849242	usd
CY2024Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1129625	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	972506	usd
CY2024Q3	us-gaap	Revenues Revenues	5000	usd
	us-gaap	Revenues Revenues	24189	usd
CY2024Q3	us-gaap	Gross Profit GrossProfit	5000	usd
	us-gaap	Gross Profit GrossProfit	24189	usd
CY2024Q3	crym	Personnel Costs PersonnelCosts	555318	usd
CY2023Q3	crym	Personnel Costs PersonnelCosts	869046	usd
	crym	Personnel Costs PersonnelCosts	1760921	usd
	crym	Personnel Costs PersonnelCosts	2360765	usd
CY2024Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	197195	usd
CY2023Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	313092	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	717631	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1099137	usd
CY2024Q3	us-gaap	Legal Fees LegalFees	88168	usd
CY2023Q3	us-gaap	Legal Fees LegalFees	160987	usd
	us-gaap	Legal Fees LegalFees	469307	usd
	us-gaap	Legal Fees LegalFees	564226	usd
CY2024Q3	us-gaap	Depreciation And Amortization DepreciationAndAmortization	30178	usd
CY2023Q3	us-gaap	Depreciation And Amortization DepreciationAndAmortization	30179	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	90536	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	299044	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	13361	usd
	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	3653043	usd
	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	1190000	usd
CY2024Q3	us-gaap	Operating Expenses OperatingExpenses	870859	usd
CY2023Q3	us-gaap	Operating Expenses OperatingExpenses	1373304	usd
	us-gaap	Operating Expenses OperatingExpenses	3038395	usd
	us-gaap	Operating Expenses OperatingExpenses	9179576	usd
CY2024Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-865859	usd
CY2023Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-1373304	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-3014206	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-9179576	usd
CY2024Q3	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	147504	usd
CY2023Q3	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	109302	usd
	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	455924	usd
	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	pure
	us-gaap	Use Of Estimates UseOfEstimates	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Use of Estimates</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of the Company’s consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of expenses during the reporting period. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, determining the fair value of the assets acquired and liabilities assumed in acquisition, determining the useful lives and potential impairment of long-lived assets and potential impairment of goodwill. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates when there are changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results could differ from those estimates.</p>
	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	245566	usd
CY2024Q3	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-6488	usd
CY2023Q3	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	28740	usd
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	19980	usd
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	10944	usd
CY2024Q3	crym	Gain Losson Contingent Royalty Liability GainLossonContingentRoyaltyLiability	-82082	usd
	crym	Gain Losson Contingent Royalty Liability GainLossonContingentRoyaltyLiability	-1487082	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-338897	usd
CY2024Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-236074	usd
CY2023Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-80562	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-2261923	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-234622	usd
CY2024Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-1101933	usd
CY2023Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-1453866	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-5276129	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-9414198	usd
CY2024Q3	us-gaap	Net Income Loss NetIncomeLoss	-1101933	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-1453866	usd
	us-gaap	Net Income Loss NetIncomeLoss	-5276129	usd
	us-gaap	Net Income Loss NetIncomeLoss	-9414198	usd
CY2024Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0
CY2024Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0
CY2023Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.01
CY2023Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.01
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.02
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.02
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.05
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.05
CY2024Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	236962413	shares
CY2024Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	236962413	shares
CY2023Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	207422054	shares
CY2023Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	207422054	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	222192774	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	222192774	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	205740483	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	205740483	shares
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	4574468	usd
CY2023Q1	crym	Stock Issued During Period Value Common Stock Issued For Current Period Services StockIssuedDuringPeriodValueCommonStockIssuedForCurrentPeriodServices	65626	usd
CY2023Q1	crym	Stock Issued During Period Value Common Stock Issued For Vested Rs Us For Current Period Services StockIssuedDuringPeriodValueCommonStockIssuedForVestedRSUsForCurrentPeriodServices	50000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition	62972	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-1598526	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	3154540	usd
CY2023Q2	crym	Stock Issued During Period Value Common Stock Issued For Current Period Services StockIssuedDuringPeriodValueCommonStockIssuedForCurrentPeriodServices	20112	usd
CY2023Q2	crym	Stock Issued During Period Value Common Stock Issued For Vested Rs Us For Current Period Services StockIssuedDuringPeriodValueCommonStockIssuedForVestedRSUsForCurrentPeriodServices	79920	usd
CY2023Q2	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition	173631	usd
CY2023Q2	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	179026	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-6361806	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	-2754577	usd
CY2023Q3	crym	Stock Issued During Period Value Common Stock Issued For Vested Rs Us For Current Period Services StockIssuedDuringPeriodValueCommonStockIssuedForVestedRSUsForCurrentPeriodServices	1384	usd
CY2023Q3	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition	141905	usd
CY2023Q3	crym	Share Issuance From Sale Of Common Stock And Warrants ShareIssuanceFromSaleOfCommonStockAndWarrants	387642	usd
CY2023Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	16000	usd
CY2023Q3	crym	Adjustment To Additional Capital Stock Options Issued For Current Period Services AdjustmentToAdditionalCapitalStockOptionsIssuedForCurrentPeriodServices	177989	usd
CY2023Q3	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	65721	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-1453866	usd
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Concentrations of Credit Risk</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash. Periodically, the Company maintains deposits in accredited financial institutions in excess of federally insured limits. The Company deposits its cash in financial institutions that it believes have high credit quality and has not experienced any losses on such accounts. Aside from this, the Company does not believe it is exposed to any unusual credit risk.</p>
	crym	Schedule Of Estimated Useful Life Of Property Plant And Equipment ScheduleOfEstimatedUsefulLifeOfPropertyPlantAndEquipment	Depreciation and amortization expense is recognized using the straight-line method over the estimated useful life of each asset, as follows:<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom; "> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Estimated<br/> Useful Life</b></span></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 89%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Machinery and equipment</span></td> <td style="width: 1%"> </td> <td style="width: 10%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">15 years</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
CY2023Q4	us-gaap	Other Short Term Borrowings OtherShortTermBorrowings	135000	usd
	crym	Monthly Processing Fee For Equipment Rental Percent MonthlyProcessingFeeForEquipmentRentalPercent	0.50	pure
CY2024Q3	us-gaap	Revenue Remaining Performance Obligation Percentage RevenueRemainingPerformanceObligationPercentage	0.10	pure
	crym	Unexercised Options Shares UnexercisedOptionsShares	19598295	shares
	crym	Unexercised Warrants Outstanding UnexercisedWarrantsOutstanding	82285183	shares
CY2024Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	787764	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	723072	usd
CY2024Q3	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross	881754	usd
CY2023Q4	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross	777833	usd
CY2024Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	93990	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	54761	usd
CY2024Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	787764	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	723072	usd
CY2024Q3	us-gaap	Depreciation Depreciation	13077	usd
	us-gaap	Depreciation Depreciation	39230	usd
CY2023Q3	us-gaap	Depreciation Depreciation	13077	usd
	us-gaap	Depreciation Depreciation	36283	usd
CY2024Q3	us-gaap	Goodwill Goodwill	0	usd
CY2023Q4	us-gaap	Goodwill Goodwill	0	usd
CY2023	us-gaap	Asset Impairment Charges AssetImpairmentCharges	1190000	usd
CY2024Q3	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	148219	usd
CY2024Q3	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	102613	usd
CY2024Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	45606	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	4230482	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	480527	usd
CY2023Q4	crym	Finite Lived Intangible Assets Impairment FiniteLivedIntangibleAssetsImpairment	-3653043	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	96912	usd
CY2024Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	17102	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	51307	usd
CY2023Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	17102	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	262761	usd
CY2024Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear	17103	usd
CY2024Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	28503	usd
CY2024Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	45606	usd
CY2023Q3	crym	Deferred Revenue Agreement Term DeferredRevenueAgreementTerm	P5Y
	us-gaap	Taxes And Licenses TaxesAndLicenses	100000	usd
CY2023Q3	us-gaap	Taxes And Licenses TaxesAndLicenses	100000	usd
	crym	Territory License Fee Agreement Description TerritoryLicenseFeeAgreementDescription	Territory License Fee, RubberRock had the obligation to pay Cryomass monthly royalties.
CY2024Q3	crym	Revenue Recognition Royalty Revenue Receivable RevenueRecognitionRoyaltyRevenueReceivable	6190	usd
CY2023Q3	crym	Territory License Fee TerritoryLicenseFee	100000	usd
CY2024Q3	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	5000	usd
CY2024Q1	us-gaap	Payments To Acquire Receivables PaymentsToAcquireReceivables	30000	cad
CY2024Q3	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	21688	usd
	us-gaap	Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Explanation RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionExplanation	three years with one three-year option to renew
	us-gaap	Payments To Acquire Receivables PaymentsToAcquireReceivables	845000	usd
CY2024Q3	crym	Contract With Customer Liability Related Partycurrent ContractWithCustomerLiabilityRelatedPartycurrent	80000	usd
	us-gaap	Debt Conversion Converted Instrument Warrants Or Options Issued1 DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1	2032500	shares
	crym	Subscriptions Agreements Description SubscriptionsAgreementsDescription	The fair value of the Warrants was determined utilizing a Binomial model considering all relevant assumptions at the dates of issuance, including the Company stock price ($0.13 for April subscription agreements, one of which is for Simon Langelier, $0.09 for May subscription agreements, $0.12 for the June subscription agreement, $0.14 for the July subscription agreement, $0.09 for the October subscription agreement, $0.08 for the November subscription agreement), term (4 years), historical volatility (152-154%), and risk-free rate (3.8% for April subscription agreements, 3.6% and 3.7% for May subscription agreements for Mario Gobbo and a private investor, respectively, 4.0% for a June subscription agreement for Health Diplomats Pte Ltd, 4.2% for a July subscription agreement, 5.0% for an October subscription agreement, 4.6% for a November subscription agreement).
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	351054	usd
	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt	351054	usd
CY2024Q3	us-gaap	Notes Payable NotesPayable	748628	usd
CY2024Q3	us-gaap	Deposit Liabilities Accrued Interest DepositLiabilitiesAccruedInterest	117592	usd
CY2024Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	739541	usd
CY2024Q3	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	739541	usd
CY2024Q3	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	144746	usd
CY2024Q3	us-gaap	Long Term Debt LongTermDebt	594795	usd
CY2023Q4	us-gaap	Other Short Term Borrowings OtherShortTermBorrowings	135000	usd
	crym	Equipment Rental Percentage EquipmentRentalPercentage	0.50	pure
CY2024Q3	us-gaap	Revenue Remaining Performance Obligation Percentage RevenueRemainingPerformanceObligationPercentage	0.10	pure
CY2024Q3	crym	Contract With Customer Liability Related Partycurrent ContractWithCustomerLiabilityRelatedPartycurrent	80000	usd
CY2023Q2	us-gaap	Stock Issued During Period Shares Issued For Services StockIssuedDuringPeriodSharesIssuedForServices	187500	shares
CY2023Q3	us-gaap	Stock Issued During Period Shares Issued For Services StockIssuedDuringPeriodSharesIssuedForServices	400000	shares
CY2023Q3	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	50000	usd
CY2023Q3	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	3748889	shares
CY2023Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	16000	usd
CY2024Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	25000	usd
CY2023Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	143289	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	509812	usd
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	11513214	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.17
CY2024Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y3M18D
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	1962017	usd
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	8085081	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0.05
CY2024Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P5Y4M24D
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	19598295	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.12
CY2024Q1	crym	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm	P6Y4M24D
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	2019574	usd
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	19598295	shares
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.12
CY2024Q2	crym	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm	P6Y1M6D
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	2038489	usd
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	19598295	shares
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.1
CY2024Q3	crym	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm	P5Y10M24D
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	2057404	usd
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	8500000	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.18
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y6M
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	1579108	usd
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	8500000	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.18
CY2023Q1	crym	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm	P8Y
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	1579108	usd
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	8500000	shares
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.18
CY2023Q2	crym	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm	P7Y8M12D
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	1579108	usd
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	3113214	shares
CY2023Q3	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0.15
CY2023Q3	crym	Sharebased Compensation Arrangement By Sharebased Payment Award Options Aggregate Intrinsic Value Granted And Vested SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsAggregateIntrinsicValueGrantedAndVested	382909	usd
CY2023Q3	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	100000	shares
CY2023Q3	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0.16
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	11513214	shares
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.18
CY2023Q3	crym	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm	P7Y7M6D
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	1962017	usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	8085081	shares
	us-gaap	Warrant Exercise Price Increase WarrantExercisePriceIncrease	0.05
	us-gaap	Stock Issued During Period Value Stock Options Exercised Net Of Tax Benefit Expense StockIssuedDuringPeriodValueStockOptionsExercisedNetOfTaxBenefitExpense	634560	usd
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	5056800	shares
	crym	Vested Expire Term VestedExpireTerm	2029-01-01
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0	pure
CY2023Q4	us-gaap	Revenue Remaining Performance Obligation Percentage RevenueRemainingPerformanceObligationPercentage	0.10	pure
CY2024Q3	crym	Contingent Royalty Liability ContingentRoyaltyLiability	2672082	usd
CY2024Q3	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2024Q3	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2024Q3	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2024Q3	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2023Q4	crym	Contract With Customer Liability Related Partycurrent ContractWithCustomerLiabilityRelatedPartycurrent		usd
CY2024Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense		usd
CY2023Q3	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill		usd
	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill		usd
CY2024Q3	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss		usd
CY2023Q3	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss		usd
	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss		usd
CY2023Q3	crym	Gain Losson Contingent Royalty Liability GainLossonContingentRoyaltyLiability		usd
	crym	Gain Losson Contingent Royalty Liability GainLossonContingentRoyaltyLiability		usd
CY2023Q3	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt		usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt		usd
CY2024Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2023Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2023Q1	crym	Stock Issued During Period Value Common Stock Issued For Prior Period Services StockIssuedDuringPeriodValueCommonStockIssuedForPriorPeriodServices		usd
CY2023Q1	crym	Stock Issued During Period Value Common Stock Issued For Vested Rs Us For Prior Period Services StockIssuedDuringPeriodValueCommonStockIssuedForVestedRSUsForPriorPeriodServices		usd
CY2024Q1	crym	Stock Issued During Period Value Common Stock Issued For Vested Rs Us For Prior Period Services StockIssuedDuringPeriodValueCommonStockIssuedForVestedRSUsForPriorPeriodServices		usd
	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss		usd
	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill		usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt		usd
	crym	Gain Losson Contingent Royalty Liability GainLossonContingentRoyaltyLiability		usd
	us-gaap	Paid In Kind Interest PaidInKindInterest		usd
	crym	Common Stock Issued For Vested Rs Us For Current Period Service CommonStockIssuedForVestedRSUsForCurrentPeriodService		usd
	crym	Adjustment Of Common Stock And Warrants Issued For Prior Period Services AdjustmentOfCommonStockAndWarrantsIssuedForPriorPeriodServices		usd
	crym	Common Stock Issued For The Current Period Services CommonStockIssuedForTheCurrentPeriodServices		usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable		usd
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets		usd
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable		usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised		usd
	crym	Debt Discount Recognized From Warrants Issued In Conjunction With Notes Payable DebtDiscountRecognizedFromWarrantsIssuedInConjunctionWithNotesPayable		usd
	crym	Stock Issued For Cancellation Of Debt StockIssuedForCancellationOfDebt		usd
CY2024Q3	crym	Finite Lived Intangible Assets Impairment FiniteLivedIntangibleAssetsImpairment		usd
CY2024Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear		usd
CY2024Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo		usd
CY2024Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree		usd
CY2024Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour		usd
CY2024Q1	crym	Sharebased Compensation Arrangement By Sharebased Payment Award Options Aggregate Intrinsic Value Granted And Vested SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsAggregateIntrinsicValueGrantedAndVested		usd
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod		shares
CY2024Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
CY2024Q1	crym	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term Forfeited SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermForfeited
CY2024Q1	crym	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeiture In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitureInPeriodTotalIntrinsicValue		usd
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross		shares
CY2024Q2	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
CY2024Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
CY2024Q2	crym	Sharebased Compensation Arrangement By Sharebased Payment Award Options Aggregate Intrinsic Value Granted And Vested SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsAggregateIntrinsicValueGrantedAndVested		usd
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod		shares
CY2024Q2	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
CY2024Q2	crym	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term Forfeited SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermForfeited
CY2024Q2	crym	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeiture In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitureInPeriodTotalIntrinsicValue		usd
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross		shares
CY2024Q3	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
CY2024Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
CY2024Q3	crym	Sharebased Compensation Arrangement By Sharebased Payment Award Options Aggregate Intrinsic Value Granted And Vested SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsAggregateIntrinsicValueGrantedAndVested		usd
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod		shares
CY2024Q3	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
CY2024Q3	crym	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term Forfeited SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermForfeited
CY2024Q3	crym	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeiture In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitureInPeriodTotalIntrinsicValue		usd
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross		shares
CY2023Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
CY2023Q1	crym	Sharebased Compensation Arrangement By Sharebased Payment Award Options Aggregate Intrinsic Value Granted And Vested SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsAggregateIntrinsicValueGrantedAndVested		usd
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod		shares
CY2023Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
CY2023Q1	crym	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term Forfeited SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermForfeited
CY2023Q1	crym	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeiture In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitureInPeriodTotalIntrinsicValue		usd
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross		shares
CY2023Q2	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
CY2023Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
CY2023Q2	crym	Sharebased Compensation Arrangement By Sharebased Payment Award Options Aggregate Intrinsic Value Granted And Vested SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsAggregateIntrinsicValueGrantedAndVested		usd
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod		shares
CY2023Q2	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
CY2023Q2	crym	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term Forfeited SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermForfeited
CY2023Q2	crym	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeiture In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitureInPeriodTotalIntrinsicValue		usd
CY2023Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod		shares
CY2023Q3	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
CY2023Q3	crym	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term Forfeited SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermForfeited
CY2023Q3	crym	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeiture In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitureInPeriodTotalIntrinsicValue		usd
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross		shares
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Entity Central Index Key EntityCentralIndexKey	0001533030
	dei	No Trading Symbol Flag NoTradingSymbolFlag	true
	dei	Security Exchange Name SecurityExchangeName	NONE
	dei	Security12b Title Security12bTitle	None

Files In Submission

Name	View Source	Status
0001213900-24-095916-index-headers.html	Edgar Link	pending
0001213900-24-095916-index.html	Edgar Link	pending
0001213900-24-095916.txt	Edgar Link	pending
0001213900-24-095916-xbrl.zip	Edgar Link	pending
crym-20240930.xsd	Edgar Link	pending
ea0218311-10q_cryomass.htm	Edgar Link	pending
ea021831101ex31-1_cryomass.htm	Edgar Link	pending
ea021831101ex31-2_cryomass.htm	Edgar Link	pending
ea021831101ex32-1_cryomass.htm	Edgar Link	pending
ea021831101ex32-2_cryomass.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
crym-20240930_lab.xml	Edgar Link	unprocessable
crym-20240930_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
ea0218311-10q_cryomass_htm.xml	Edgar Link	completed
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
crym-20240930_cal.xml	Edgar Link	unprocessable
crym-20240930_def.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CRYM
Cryomass Technologies, Inc. Stock $crym

2024 Q4 Form 10-Q Financial Statement

#000121390024095916 Filed on November 08, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CRYM Cryomass Technologies, Inc. Stock $crym

2024 Q4 Form 10-Q Financial Statement

#000121390024095916 Filed on November 08, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CRYM
Cryomass Technologies, Inc. Stock $crym